Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Anaptysbio (ANAB) Research & Development (2016 - 2025)

Anaptysbio's Research & Development history spans 10 years, with the latest figure at $25.6 million for Q4 2025.

  • For Q4 2025, Research & Development fell 39.99% year-over-year to $25.6 million; the TTM value through Dec 2025 reached $136.0 million, down 17.01%, while the annual FY2025 figure was $136.0 million, 17.01% down from the prior year.
  • Research & Development reached $25.6 million in Q4 2025 per ANAB's latest filing, down from $31.4 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $42.6 million in Q4 2024 to a low of $20.8 million in Q2 2022.
  • Average Research & Development over 5 years is $31.0 million, with a median of $31.1 million recorded in 2023.
  • Peak YoY movement for Research & Development: soared 57.95% in 2023, then tumbled 39.99% in 2025.
  • A 5-year view of Research & Development shows it stood at $26.8 million in 2021, then dropped by 12.71% to $23.4 million in 2022, then skyrocketed by 43.43% to $33.5 million in 2023, then increased by 27.04% to $42.6 million in 2024, then tumbled by 39.99% to $25.6 million in 2025.
  • Per Business Quant, the three most recent readings for ANAB's Research & Development are $25.6 million (Q4 2025), $31.4 million (Q3 2025), and $37.8 million (Q2 2025).